The clinical value of optimized mNGS technology in the diagnosis of pathogens in patients with bloodstream infections

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200059992

Enrollment

Unknown

Registered

2022-05-14

Start date

2022-05-01

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bloodstream infections

Interventions

Gold Standard:The traditional microbial detection

Index test:Optimized mNGS technology

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. For patients suspected of blood flow infection, blood should be collected before antibiotic use; (patients with hematological tumors such as severe agranulocytosis and severe immunodeficiency); 2. After admission, enough blood can be taken for CMTs (traditional detection method) and two mNGS detection before and after optimization; 3. Complete clinical information can be obtained (including but not limited to clinical culture results and drug sensitivity test results).

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Sensitivity;Specificity;	—

Countries

China

Contacts

Public ContactJuan Huang

Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital

juanjuan028@126.com+86 18108189376

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026